CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...
CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...
The former wife of DOC Commissioner Paul Schnell has been sentenced to three years in prison for trying to kill their ...
CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...
Jayden Wilsey was the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease after federal approval in 2024.
The latest edition of La Marató de 3Cat raised 10 million euros, which will fund 36 research projects on respiratory diseases ...
Research and development expenses for the fiscal quarter ended September 30, 2025 were $2.5 million compared with $4.6 million for the fiscal quarter ended September 30, 2024. The decrease of $2.1 ...
CalciMedica (CALC) announced a poster presentation titled, “Store-Operated Calcium-Channel Inhibitor Auxora Improves Kidney Function Following Ischemia-Induced AKI in Rats” at the American Society of ...
EXTON, PA — Lungpacer Medical announced the enrollment of the first six patients in its landmark STARI (STimulation to ...
Researchers have proposed a personalised, multi-target therapeutic approach to treat sepsis by dynamically regulating key ...
Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback